5 Best Stocks to Buy According to John Paulson

4. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Paulson’s Stake Value: $214,074,000
Percentage of John Paulson’s 13F Portfolio: 4.91%
Number of Hedge Fund Holders: 77

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a subsidiary of AstraZeneca, is a pharmaceutical company. The company was incorporated in 1992 and stands fourth on the list of 10 best stocks to buy according to John Paulson. Alexion currently has a $40.34 billion market capitalization. 

On July 6, AstraZeneca PLC (NASDAQ: AZN) obtained approval from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals (NASDAQ: ALXN). The deal valued at $39 billion was previously cleared in the U.S., Japan, and several other countries. The main purpose of this acquisition is to create a pioneer in immunology and precision medicines. On May 5, AZN Oppenheimer analyst Hartaj Singh upgraded Alexion Pharmaceuticals to “Outperform” from “Perform” with a price target of $205. 

Paulson & Co holds 1.4 million shares in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), worth over $214 million, representing 4.91% of their portfolio. In addition, there were 77 hedge funds in our database that held stakes in Alexion Pharmaceuticals at the end of the first quarter of 2021, the same as in the third quarter.

ClearBridge Investments, in their first quarter 2021 investor letter, mentioned Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Here is what the fund said:

“We also sold biotechnology holding Alexion Pharmaceuticals ahead of its acquisition by AstraZeneca but expect to redouble our efforts in health care through the rest of the year. We see good growth potential in the sector and after full due diligence, have been busy populating our wish list with new names we would like to own.”